Citeline

Supplies the industry's reference datasets on trials, sites, and investigators, used for feasibility, competitive landscape, and site selection. It informs enrollment planning rather than delivering patients.

Enterprise data subscription, typically annual per-seat or per-module.

Whatever the structure, convert it to cost per randomized patient before you compare proposals. Cost per referral is the number vendors prefer to quote and the number that tells you least.

• Deepest commercial dataset on trial and investigator activity
• Essential for competitive-landscape and site-saturation analysis

• It is a subscription, not a solution — someone still has to act on it
• Cost is meaningful for a small biotech running one study

Worth it when: Feasibility and site selection teams who need landscape data before committing sites.

Not worth it when: A sponsor whose actual problem is that sites already selected are not enrolling.

• Deep 6 AIMines clinical records, including unstructured notes, to find eligible patients.
• TrialbeePatient matching and orchestration across multiple referral sources.

• Deep 6 AI vs Citeline — Patient-level record mining versus market-level trial data.

Ask for the referral-to-randomization ratio on three studies resembling yours, in the same indication and the same countries. If a vendor will not give it, that is the answer. If your enrollment forecast itself is the shaky part, our sister publication Rock Enroll covers forecasting and rescue in depth.